Stephen D Wiviott
Overview
Explore the profile of Stephen D Wiviott including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
257
Citations
24611
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Small A, Melloni G, Kamanu F, Bergmark B, Bonaca M, ODonoghue M, et al.
JAMA Cardiol
. 2024 Feb;
9(4):357-366.
PMID: 38416462
Importance: Polygenic risk scores (PRSs) have proven to be as strong as or stronger than established clinical risk factors for many cardiovascular phenotypes. Whether this is true for aortic stenosis...
12.
Zimerman A, Wiviott S, Park J, Murphy S, Ran X, Bramson C, et al.
J Clin Lipidol
. 2023 Dec;
18(2):e261-e268.
PMID: 38158248
Background: Angiopoietin-like protein 3 (ANGPTL3) is a novel therapeutic target for hyperlipidemia. Vupanorsen, an antisense oligonucleotide targeting ANGPTL3, reduced triglycerides up to 57% in a phase 2b trial, but caused...
13.
Patel S, Morrow D, Bellavia A, Berg D, Bhatt D, Jarolim P, et al.
Eur J Heart Fail
. 2023 Dec;
26(2):260-269.
PMID: 38131261
Aim: N-terminal pro-B-type natriuretic peptide (NT-proBNP) concentrations are lower in patients with obesity. The interaction between body mass index (BMI) and NT-proBNP with respect to heart failure risk remains incompletely...
14.
Moura F, Berg D, Bellavia A, Dwyer J, Mosenzon O, Scirica B, et al.
Diabetes Care
. 2023 Aug;
46(10):1807-1815.
PMID: 37556796
Objective: To develop a risk assessment tool to identify patients with type 2 diabetes (T2D) at higher risk for kidney disease progression and who might benefit more from sodium-glucose cotransporter...
15.
Grinspoon S, Fitch K, Zanni M, Fichtenbaum C, Umbleja T, Aberg J, et al.
N Engl J Med
. 2023 Jul;
389(8):687-699.
PMID: 37486775
Background: The risk of cardiovascular disease is increased among persons with human immunodeficiency virus (HIV) infection, so data regarding primary prevention strategies in this population are needed. Methods: In this...
16.
Berg D, Moura F, Bellavia A, Scirica B, Wiviott S, Bhatt D, et al.
J Am Coll Cardiol
. 2023 Jun;
81(25):2391-2402.
PMID: 37344040
Background: Risk of atherothrombotic events is not uniform in patients with type 2 diabetes mellitus (T2DM). Tailored risk assessment may help guide selection of pharmacotherapies for cardiovascular primary and secondary...
17.
Wiviott S, Berg D
J Am Coll Cardiol
. 2023 Jun;
81(25):2388-2390.
PMID: 37344039
No abstract available.
18.
Schechter M, Wiviott S, Raz I, Goodrich E, Rozenberg A, Yanuv I, et al.
Lancet Diabetes Endocrinol
. 2023 Mar;
11(4):233-241.
PMID: 36878239
Background: In people with type 2 diabetes at high risk of cardiovascular or kidney disease, sodium-glucose co-transporter 2 (SGLT2) inhibitors consistently reduce the risk of hospitalisations for heart failure. Less...
19.
Zelniker T, Wiviott S, Mosenzon O, Goodrich E, Jarolim P, Cahn A, et al.
JAMA Cardiol
. 2023 Mar;
8(5):503-509.
PMID: 36857035
Importance: Dapagliflozin reduces the risk of hospitalizations for heart failure and the progression of chronic kidney disease in patients with and without type 2 diabetes (T2D), whereas the effects on...
20.
Gaba P, ODonoghue M, Park J, Wiviott S, Atar D, Kuder J, et al.
Circulation
. 2023 Feb;
147(16):1192-1203.
PMID: 36779348
Background: Low-density lipoprotein cholesterol (LDL-C) is a well-established risk factor for atherosclerotic cardiovascular disease. However, the optimal achieved LDL-C level with regard to efficacy and safety in the long term...